The halls of power in Washington have witnessed another departure, this one from the Food and Drug Administration where Commissioner Marty Makary submitted his resignation on Tuesday. The move comes against a backdrop of reported White House dissatisfaction and mounting questions about his leadership of the sprawling federal agency.
Now, let us be clear about what happened here. Reports surfaced late last week suggesting President Trump was considering removing Makary from his post. Those reports proved prescient, though the exact nature of the departure remains somewhat murky, as these things often do in the nation’s capital.
When pressed by reporters before his departure for China, Trump declined to specify whether he had requested Makary’s resignation or outright dismissed him. “I don’t want to say, but Marty’s a great guy,” the president stated, describing Makary as a friend and “a wonderful man” who would “go on and lead a good life.”
The resignation follows a period of turbulence at the FDA. Makary, a surgeon and health researcher who gained prominence among conservatives for his criticism of COVID-19 health measures during the pandemic, faced mounting criticism on multiple fronts. Republican senators had been waiting for a promised safety review of the abortion pill mifepristone that Makary committed to pursuing during his confirmation process. That review never materialized.
Beyond that specific issue, Makary encountered difficulties managing the FDA’s extensive bureaucracy. Reports indicate he struggled to win the confidence of agency staff following mass layoffs and leadership changes. The agency found itself embroiled in controversies where scientific principles appeared to take a back seat to political considerations.
In his resignation message to Trump, which the president shared publicly, Makary emphasized his accomplishments. “During my tenure, I announced 50 major FDA reforms,” Makary wrote, contrasting his tenure with the previous administration. He highlighted reducing drug review times from a year to one or two months and advancing guidance on psychedelics.
Trump, for his part, publicly thanked Makary for his service. “I want to thank Dr. Marty Makary for having done a great job at the FDA,” Trump wrote. “So much was accomplished under his leadership. He was a hard worker, who was respected by all, and will go on to have an outstanding career in Medicine.”
The president announced that Kyle Diamantas would assume the role in an acting capacity, describing him as “a very talented person.” Trump noted that many individuals are interested in the position, calling it “a very important job.”
This departure raises questions about the direction of the FDA at a critical time. The agency oversees everything from food safety to pharmaceutical approvals, touching the lives of every American. Leadership stability matters in such an institution, and the circumstances surrounding Makary’s exit suggest all was not well behind the scenes.
The truth, as it often does, likely lies somewhere between the official statements of mutual respect and the reports of struggles and potential termination. What remains undeniable is that Makary’s tenure proved shorter and more contentious than anyone anticipated when he took office with promises of reform and streamlined operations.
As Washington turns the page on another chapter, the question becomes who will lead the FDA forward and whether they can navigate the competing demands of political leadership and scientific integrity that appear to have complicated Makary’s brief time at the helm.
Related: Michigan Lawmakers Introduce Assisted Suicide Bill with Strict Safeguards
